BioSpace News Archive

Ocugen, Inc. announced the U.S. Food and Drug Administration granted orphan drug designation for OCU400, Ocugen’s novel gene therapy, for the treatment of NR2E3 mutation-associated retinal degenerative disease.

REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will host an analyst and investor event focused on its ophthalmology program, including its lead product candidate RGX-314, on Thursday, February 21, 2019, from 9:00 a.m. to 12:00 p.m. EST in New York City.

Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received Breakthrough Device Designation from the Center of Devices and Radiological Health of the U.S. Food and Drug Administration on January 3, 2019 for the Lumipulse G β-Amyloid Ratio quantitative in vitro diagnostic test.

MAT Physician Experts And Recovery Centers Of America Ceo To Discuss The Importance Of Mat As Treatment Tool In Opioid Epidemic

Today, Sciton Inc., a leading manufacturer of medical and aesthetic laser and light source technologies, announced that it has received an expansion of the clearances for their medical device license issued by Health Canada for their diVaⓇ product to include a new indication “for the treatment of the symptoms of Genitourinary Syndrome of Menopause (GSM)” in peri and post-menopausal women.

ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results.

Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for fourth quarter and full year ended December 31, 2018 before the open of U.S. financial markets on Wednesday, February 27, 2019.

Tmunity Therapeutics is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy

She has joined the Board as Michael Ross, co-Chairman, steps down from Catabasis’ Board of Directors.

Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium